LUNG: Q3 revenue grew 6% as operating costs and losses declined

What happened

In the third quarter, revenue grew 6% and gross margin improved to 76%, which means profit per sale rose. Operating expenses fell 18% year over year, and net loss and Adjusted EBITDA loss both narrowed. Full-year 2026 revenue guidance remains $90 million–$92 million.

Confirmed

Global impact / market context

Faster revenue plus lower operating costs means the company keeps more cash from each sale, reducing the need for borrowed money or new funding. The unchanged $90 million–$92 million guidance signals management expects the improvement to hold through 2026.

Analyst inference

A medical device maker returning to growth while cutting costs can support investor confidence, because past losses had raised questions about cash needs. The maintained guidance suggests the quarter's gains reflect steady demand rather than a one-time event.

Analyst inference

What to watch

1. Whether full-year 2026 revenue lands within the guided $90 million–$92 million range, since the article keeps that target unchanged. Confirmed
2. Watch whether management explains how the 18% cut in operating expenses was achieved, and whether those savings can repeat in future quarters. Proposed
3. Track whether the 76% gross margin holds, because a slip would mean less profit per sale and could slow the path to breaking even. Analyst inference

Evidence

• Original source link unavailable